Pharmaceuticals

AI-generated in silico data in patent applications

The impact of AI-generated in silico data on pharma patent applications In silico data generated using AI platforms can identify existing medication candidates and match them with diseases and conditions that do not yet have a cure much quicker and more reliably than a human will ever be able to do. However, it...

Read more

Patent licensing trends in the UK pharmaceutical sector

2018 was billed by some in the industry as the year of pharma M&As. However, as of September, we still haven’t seen the acquisition values that were expected following a rather barren 2017. What we have seen are record high patent licensing deals. If your company is built on a...

Read more

M&A Deals and the Pharmaceutical sector: Are your IP ducks in a row?

2018 has so far been a productive year for M&A deals in the pharmaceutical sector. At the start of the year, Celgene acquired both Impact Biomedicines for around $7 billion and Juno Therapeutics, Inc for a total of approximately $9 billion. In March, Sanofi completed its $11.6 billion acquisition of Bioveratis....

Read more

Could the new EU Medical Devices Regulation put the UK MedTech industry in peril?

There has been much debate in recent years about the difficulty in attracting both private and public funds into the UK biotech industry.  At certain points, it seemed like a disproportionate percentage of the funding that was invested into UK biotech came from the US.  It is likely that there...

Read more

UK Supreme Court judgment in long-running dispute between Eli Lilly and Actavis on the combination therapy pemetrexed + vitamin B12 results in significant outcomes for patent infringement in the UK

In a judgment issued on 12 July, the UK Supreme Court made some significant changes in the law of UK patent infringement which could have far reaching consequences, especially in the pharmaceutical sector. In particular, they addressed the issue of infringement by equivalents not otherwise falling within the literal claim scope and...

Read more